Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer
Y-mAbs Therapeutics Inc (NASDAQ: YMAB) recently concluded a Type B meeting with the FDA regarding omburtamab in CNS/leptomeningeal metastasis from neuroblastoma.
